(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Brilliant Acquisition Corporation, BioCardia, and Inovio Pharmaceuticals.

The three biggest losers today are Canopy Growth, Brooge Energy Limited , and Avadel Pharmaceuticals plc.

Winners today

1. Brilliant Acquisition Corporation (BRLIR) – 27.24%

NASDAQ ended the session with Brilliant Acquisition Corporation rising 27.24% to $0.18 on Wednesday while NASDAQ dropped 0.18% to $13,791.65.

Yearly Top and Bottom Value

Brilliant Acquisition Corporation’s stock is valued at $0.18 at 17:32 EST, above its 52-week high of $0.18.

More news about Brilliant Acquisition Corporation.

2. BioCardia (BCDAW) – 26.6%

NASDAQ ended the session with BioCardia rising 26.6% to $0.95 on Wednesday while NASDAQ slid 0.18% to $13,791.65.

Yearly Top and Bottom Value

BioCardia’s stock is valued at $0.95 at 17:32 EST, under its 52-week high of $1.03 and way higher than its 52-week low of $0.69.

More news about BioCardia.

3. Inovio Pharmaceuticals (INO) – 20.12%

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

NASDAQ ended the session with Inovio Pharmaceuticals rising 20.12% to $0.52 on Wednesday, after two successive sessions in a row of losses. NASDAQ dropped 0.18% to $13,791.65, after two sequential sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, Inovio Pharmaceuticals has a trailing twelve months EPS of $-0.89.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -87.1%.

More news about Inovio Pharmaceuticals.

4. Bionano Genomics (BNGOW) – 16%

NASDAQ ended the session with Bionano Genomics rising 16% to $0.02 on Wednesday while NASDAQ slid 0.18% to $13,791.65.

More news about Bionano Genomics.

5. Aspen Group (ASPU) – 13.46%

Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.

NASDAQ ended the session with Aspen Group jumping 13.46% to $0.15 on Wednesday, after three successive sessions in a row of losses. NASDAQ slid 0.18% to $13,791.65, after two sequential sessions in a row of gains, on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, Aspen Group has a trailing twelve months EPS of $-0.39.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.26%.

More news about Aspen Group.

6. BioXcel Therapeutics (BTAI) – 12.25%

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of rare forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

NASDAQ ended the session with BioXcel Therapeutics jumping 12.25% to $8.85 on Wednesday, after two sequential sessions in a row of gains. NASDAQ fell 0.18% to $13,791.65, after two successive sessions in a row of gains, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, BioXcel Therapeutics has a trailing twelve months EPS of $-6.64.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -151.47%.

More news about BioXcel Therapeutics.

7. Niu Technologies (NIU) – 7.43%

Niu Technologies designs, manufactures, and sells smart electric scooters in the People's Republic of China. The company offers RQi, NQi, MQi, SQi, UQi, and Gova series electric scooters and motorcycles; KQi series one kick-scooters; BQi series e-bikes; and Niu Aero Sports Bicycles. It also provides accessories and spare parts under the NIU brand name comprising scooter accessories, such as raincoats, gloves, knee pads, storage baskets and tail boxes, smart phone holders, backrests, and locks; lifestyle accessories, which includes T-shirts, coats, sweaters and hoodies, jeans, hats, bags, jewelry, notebook, badges, key chain, and mugs; and performance upgrade components that comprises of upgraded wheels, shock absorbers, brake calipers, and carbon fiber body panels. In addition, the company, through its NIU app, offers online repair request, DIY repairs, service station locator, theft reporting, smart check, and smart services, as well as NIU cover, which provides insurance services. Niu Technologies sells and services its products through city partners and franchised stores, distributors, and third-party e-commerce platforms and the company's online store. The company was incorporated in 2014 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with Niu Technologies rising 7.43% to $4.48 on Wednesday while NASDAQ slid 0.18% to $13,791.65.

Earnings Per Share

As for profitability, Niu Technologies has a trailing twelve months EPS of $-0.14.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -6.41%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Niu Technologies’s stock is considered to be oversold (<=20).

More news about Niu Technologies.

8. Beyond Meat (BYND) – 7.06%

Beyond Meat, Inc. develops, manufactures, markets, and sells plant-based meat products in the United States and internationally. The company sells a range of plant-based meat products across the platforms of beef, pork, and poultry. It sells its products through grocery, mass merchandiser, club, convenience, and natural retailer channels, as well as various food-away-from-home channels, including restaurants, foodservice outlets, and schools. The company was formerly known as Savage River, Inc. and changed its name to Beyond Meat, Inc. in September 2018. Beyond Meat, Inc. was founded in 2009 and is headquartered in El Segundo, California.

NASDAQ ended the session with Beyond Meat jumping 7.06% to $14.10 on Wednesday, after five sequential sessions in a row of gains. NASDAQ fell 0.18% to $13,791.65, after two sequential sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Beyond Meat has a trailing twelve months EPS of $-5.4.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 44.4% and 51.9%, respectively.

Yearly Top and Bottom Value

Beyond Meat’s stock is valued at $14.10 at 17:32 EST, way below its 52-week high of $44.59 and way higher than its 52-week low of $9.81.

More news about Beyond Meat.

9. ATIF Holdings Limited (ATIF) – 6.54%

ATIF Holdings Limited, a consulting company, provides financial consulting services to small and medium-sized enterprises in Asia. It primarily helps clients going public on the OTC markets and exchanges in the United States. The company was incorporated in 2015 and is headquartered in Rancho Cucamonga, California.

NASDAQ ended the session with ATIF Holdings Limited jumping 6.54% to $1.63 on Wednesday, after three consecutive sessions in a row of losses. NASDAQ dropped 0.18% to $13,791.65, after two consecutive sessions in a row of gains, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, ATIF Holdings Limited has a trailing twelve months EPS of $-0.07.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.23%.

Volume

Today’s last reported volume for ATIF Holdings Limited is 81 which is 97.65% below its average volume of 3453.

Earnings Before Interest, Taxes, Depreciation, and Amortization

ATIF Holdings Limited’s EBITDA is 4.6.

Yearly Top and Bottom Value

ATIF Holdings Limited’s stock is valued at $1.63 at 17:32 EST, way below its 52-week high of $2.87 and way above its 52-week low of $1.23.

More news about ATIF Holdings Limited.

10. BeiGene (BGNE) – 5.73%

BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company is also developing Zanubrutinib to treat B-cell malignancies; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Ociperlimab for treating solid tumors, cervical cancer, and NSCLC; Surzebiclimab, BGB-A445, BGB-15025, Lifirafenib, BGB-24714, and BGB-B167 to treat solid tumors; BGB-10188 for treating solid tumors, B-cell lymphoid malignancies, and B-cell malignancies; BGB-11417 to treat R/R chronic lymphocytic leukemia/ small lymphocytic lymphoma, R/R mantle cell lymphoma, Mature B-cell malignancies, Myeloid malignancies, and R/R multiple myeloma; BGB-16673 for B-cell malignancies; and BGB-23339 for Inflammation and immunology. The company has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Enlivex Therapeutics Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

NASDAQ ended the session with BeiGene jumping 5.73% to $191.22 on Wednesday, following the last session’s upward trend. NASDAQ fell 0.18% to $13,791.65, after two sequential sessions in a row of gains, on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, BeiGene has a trailing twelve months EPS of $-18.57.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -38.18%.

Yearly Top and Bottom Value

BeiGene’s stock is valued at $191.22 at 17:32 EST, way below its 52-week high of $280.62 and way higher than its 52-week low of $124.46.

Volume

Today’s last reported volume for BeiGene is 209807 which is 5.67% below its average volume of 222420.

Volatility

BeiGene’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.19%, a negative 1.09%, and a positive 2.03%.

BeiGene’s highest amplitude of average volatility was 0.77% (last week), 1.52% (last month), and 2.03% (last quarter).

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 37.7% and 37.5%, respectively.

More news about BeiGene.

Losers Today

1. Canopy Growth (CGC) – -21.46%

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

NASDAQ ended the session with Canopy Growth dropping 21.46% to $0.46 on Wednesday, after two successive sessions in a row of gains. NASDAQ dropped 0.18% to $13,791.65, after two successive sessions in a row of gains, on what was a somewhat down trend exchanging session today.

: analyst cuts canopy growth price target to $0Eight Capital analyst Ty Collin on Wednesday cut his price target for Canadian cannabis company Canopy Growth Corp. to $0 from C$1.75 ($1.32) a share and reiterated a sell rating on the stock.

Earnings Per Share

As for profitability, Canopy Growth has a trailing twelve months EPS of $-7.3.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -151.11%.

Volatility

Canopy Growth’s last week, last month’s, and last quarter’s current intraday variation average was a positive 13.49%, a negative 0.95%, and a positive 4.84%.

Canopy Growth’s highest amplitude of average volatility was 22.10% (last week), 7.41% (last month), and 4.84% (last quarter).

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 96.3% and 62.9%, respectively.

Moving Average

Canopy Growth’s value is way below its 50-day moving average of $0.93 and way below its 200-day moving average of $2.23.

Previous days news about Canopy Growth

• Canopy growth (cgc) improves liquidity with another selloff. According to Zacks on Monday, 3 July, "As a result, Canopy Growth is now better positioned to achieve its goal of becoming an asset-light, North America-focused cannabis business.", "As the cannabis industry continues to evolve, Canopy Growth remains committed to delivering innovative products that enhance the lives of consumers while creating sustainable value for shareholders."

More news about Canopy Growth.

2. Brooge Energy Limited (BROGW) – -10.45%

NASDAQ ended the session with Brooge Energy Limited falling 10.45% to $0.02 on Wednesday while NASDAQ fell 0.18% to $13,791.65.

More news about Brooge Energy Limited .

3. Avadel Pharmaceuticals plc (AVDL) – -8.28%

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

NASDAQ ended the session with Avadel Pharmaceuticals plc sliding 8.28% to $15.11 on Wednesday, following the last session’s downward trend. NASDAQ dropped 0.18% to $13,791.65, after two sequential sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Avadel Pharmaceuticals plc has a trailing twelve months EPS of $-2.32.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1662.06%.

More news about Avadel Pharmaceuticals plc.

4. Arcutis Biotherapeutics (ARQT) – -8.18%

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

NASDAQ ended the session with Arcutis Biotherapeutics falling 8.18% to $8.75 on Wednesday while NASDAQ fell 0.18% to $13,791.65.

Earnings Per Share

As for profitability, Arcutis Biotherapeutics has a trailing twelve months EPS of $-5.65.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -166.32%.

Moving Average

Arcutis Biotherapeutics’s worth is way below its 50-day moving average of $10.60 and way below its 200-day moving average of $14.59.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 5.3% and 36.5%, respectively.

More news about Arcutis Biotherapeutics.

5. Generac Holdlings (GNRC) – -7.57%

Generac Holdings Inc. designs, manufactures, and sells power generation equipment, energy storage systems, energy management devices and solutions, and other power products for the residential, light commercial, and industrial markets worldwide. The company offers residential automatic standby generators, automatic transfer switch, air-cooled engine residential standby generators, and liquid-cooled engine generators; residential storage solution consists of a system of batteries, an inverter, photovoltaic optimizers, power electronic controls, and other components; Mobile Link, a remote monitoring system for home standby generators; smart home solutions, such as smart thermostats and a suite of home monitoring products; smart water heater controllers; residential clean energy solutions; and portable and inverter generators; outdoor power equipment, including trimmers, field and brush mowers, log splitters, stump grinders, chipper shredders, lawn and leaf vacuums, and pressure washers and water pumps; and battery-powered turf care products. It also provides commercial and industrial products comprising cleaner-burning natural gas fueled generators; light-commercial standby generators and related transfer switches; stationary generators and related transfer switches; single-engine industrial generators; industrial standby generators; industrial transfer switches; light towers, mobile generators, and mobile energy storage systems; and aftermarket service parts and product accessories. The company distributes its products through independent residential dealers, industrial distributors and dealers, national and regional retailers, e-commerce partners, electrical, HVAC and solar wholesalers, catalogs, equipment rental companies and distributors, and solar installers; and directly to end users. The company was founded in 1959 and is headquartered in Waukesha, Wisconsin.

NYSE ended the session with Generac Holdlings falling 7.57% to $139.21 on Wednesday, after four sequential sessions in a row of gains. NYSE fell 0.48% to $15,841.67, after three successive sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Generac Holdlings has a trailing twelve months EPS of $4.45.

PE Ratio

Generac Holdlings has a trailing twelve months price to earnings ratio of 31.28. Meaning, the purchaser of the share is investing $31.28 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.96%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Generac Holdlings’s EBITDA is 98.04.

Sales Growth

Generac Holdlings’s sales growth is negative 24.5% for the ongoing quarter and 1.7% for the next.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Generac Holdlings’s stock is considered to be oversold (<=20).

More news about Generac Holdlings.

6. Black Diamond Therapeutics (BDTX) – -7.13%

Black Diamond Therapeutics, Inc., a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial. It also develops BDTX-4933, a brain penetrant RAF MasterKey inhibitor, designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers, expected to initiate Phase 1 clinical trial. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with Black Diamond Therapeutics falling 7.13% to $4.69 on Wednesday, following the last session’s downward trend. NASDAQ slid 0.18% to $13,791.65, after two successive sessions in a row of gains, on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, Black Diamond Therapeutics has a trailing twelve months EPS of $-8.03.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -63.92%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 15.9% and 20%, respectively.

Yearly Top and Bottom Value

Black Diamond Therapeutics’s stock is valued at $4.69 at 17:32 EST, way below its 52-week high of $6.85 and way above its 52-week low of $1.18.

Volume

Today’s last reported volume for Black Diamond Therapeutics is 1481880 which is 62.94% below its average volume of 3998780.

More news about Black Diamond Therapeutics.

7. LendingTree (TREE) – -6.87%

LendingTree, Inc., through its subsidiary, LT Intermediate Company, LLC, operates online consumer platform in the United States. It operates through three segments: Home, Consumer, and Insurance. The Home segment offers purchase mortgage, refinance mortgage, reverse mortgage, and home equity loans; lines of credit; and real estate brokerage services. The Consumer segment provides credit cards; personal, small business, student, and auto loans; deposit accounts; and other credit products, such as credit repair and debt settlement services. The Insurance segment includes information, tools, and access to insurance quote products, including home and automobile, through which consumers are matched with insurance lead aggregators to obtain insurance offers. In addition, the company offers QuoteWizard.com, a marketplace for insurance comparison; ValuePenguin, a personal finance website that offers consumers objective analysis on various financial topics from insurance to credit cards; and Stash, a consumer investing and banking platform that offers a suite of personal investment accounts, traditional and Roth IRAs, custodial investment accounts, and banking services, including checking accounts and debit cards with a Stock-Back rewards program. The company was formerly known as Tree.com, Inc. and changed its name to LendingTree, Inc. in January 2015. LendingTree, Inc. was incorporated in 1996 and is based in Charlotte, North Carolina.

NASDAQ ended the session with LendingTree dropping 6.87% to $21.81 on Wednesday while NASDAQ fell 0.18% to $13,791.65.

Earnings Per Share

As for profitability, LendingTree has a trailing twelve months EPS of $-12.81.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -57.24%.

Sales Growth

LendingTree’s sales growth is negative 26% for the ongoing quarter and negative 18.3% for the next.

Volatility

LendingTree’s last week, last month’s, and last quarter’s current intraday variation average was 2.95%, 0.90%, and 3.85%.

LendingTree’s highest amplitude of average volatility was 4.31% (last week), 3.34% (last month), and 3.85% (last quarter).

More news about LendingTree.

8. Cardlytics (CDLX) – -6.84%

Cardlytics, Inc. operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing. The company was incorporated in 2008 and is headquartered in Atlanta, Georgia.

NASDAQ ended the session with Cardlytics sliding 6.84% to $5.86 on Wednesday, following the last session’s downward trend. NASDAQ slid 0.18% to $13,791.65, after two sequential sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, Cardlytics has a trailing twelve months EPS of $-11.96.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -102.69%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Cardlytics’s EBITDA is 5.19.

Yearly Top and Bottom Value

Cardlytics’s stock is valued at $5.86 at 17:32 EST, way below its 52-week high of $24.05 and way above its 52-week low of $2.57.

Revenue Growth

Year-on-year quarterly revenue growth declined by 5.3%, now sitting on 294.94M for the twelve trailing months.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 47.7% and 60%, respectively.

More news about Cardlytics.

9. Wayfair (W) – -6.09%

Wayfair Inc. engages in the e-commerce business in the United States and internationally. The company provides approximately fourty million products for the home sector under various brands. It offers online selections of furniture, décor, housewares, and home improvement products through its sites, including Wayfair, Joss & Main, AllModern, Birch Lane, Perigold, and Wayfair Professional. The company was founded in 2002 and is headquartered in Boston, Massachusetts.

NYSE ended the session with Wayfair falling 6.09% to $64.15 on Wednesday while NYSE slid 0.48% to $15,841.67.

Earnings Per Share

As for profitability, Wayfair has a trailing twelve months EPS of $-13.9.

Volume

Today’s last reported volume for Wayfair is 4709130 which is 13.92% below its average volume of 5471160.

Volatility

Wayfair’s last week, last month’s, and last quarter’s current intraday variation average was 3.02%, 2.11%, and 3.63%.

Wayfair’s highest amplitude of average volatility was 3.02% (last week), 2.92% (last month), and 3.63% (last quarter).

More news about Wayfair.

10. MicroVision (MVIS) – -5.79%

MicroVision, Inc. develops and sells lidar sensors used in automotive safety and autonomous driving applications. Its laser beam scanning technology is based on micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company also develops micro-display concepts and designs for head-mounted augmented reality (AR) headsets, as well as 1440i MEMS module supporting AR headsets; interactive display solutions for the smart speakers market; and Consumer Lidar used in smart home systems. In addition, it develops 1st Generation LRL module. The company sells its products primarily to original equipment manufacturers and original design manufacturers. MicroVision, Inc. was founded in 1993 and is headquartered in Redmond, Washington.

NASDAQ ended the session with MicroVision sliding 5.79% to $4.23 on Wednesday, following the last session’s downward trend. NASDAQ dropped 0.18% to $13,791.65, after two sequential sessions in a row of gains, on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, MicroVision has a trailing twelve months EPS of $-0.33.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -62.05%.

Sales Growth

MicroVision’s sales growth for the current quarter is 154.8%.

More news about MicroVision.

Stay up to date with our winners and losers daily report